Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | SELE | P16581 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29749517 | 1.00 | NPC1 (0.42) | NPC1RAB9AKDM4CL3MBTL1MEN1 | |
| SCHEMBL19715580 | 0.88 | KDM4C (0.41) | NPC1RAB9AKDM4CL3MBTL1MEN1 | |
| SCHEMBL28796337 | 0.88 | NPC1 (0.50) | NPC1RAB9AKDM4CL3MBTL1MEN1 | |
| SCHEMBL29749639 | 0.88 | NPC1 (0.50) | NPC1RAB9AKDM4CL3MBTL1MEN1 | |
| SCHEMBL23387990 | 0.82 | NPC1 (0.40) | NPC1RAB9AKDM4CL3MBTL1MEN1 | |
| SCHEMBL7482938 | 0.80 | NPC1 (0.46) | NPC1RAB9AKDM4CL3MBTL1MEN1 | |
| SCHEMBL19127703 | 0.77 | NPC1 (0.51) | NPC1RAB9AKDM4CL3MBTL1MEN1 | |
| SCHEMBL3889222 | 0.76 | KDM4C (0.46) | NPC1RAB9AKDM4CL3MBTL1MEN1 | |
| SCHEMBL19715695 | 0.75 | KDM4C (0.35) | NPC1RAB9AKDM4CL3MBTL1MEN1 | |
| SCHEMBL17878832 | 0.75 | KDM4C (0.43) | NPC1RAB9AKDM4CL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503471-B2 | Triazatricycle compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20230015242-A1 | TRIAZATRICYCLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| EP-4061814-A1 | TRIAZATRICYCLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2022-09-28 | — | — | EP | disclosed |
| CN-114667286-A | Triazatricycles for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2022-06-24 | — | — | CN | disclosed |
| WO-2021099285-A1 | TRIAZATRICYCLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021099285-A1 | TRIAZATRICYCLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2021-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503471-B2 | Triazatricycle compounds for the treatment of autoimmune disease | SSB, HLA-DRB1, PKD1 | NPC1 922/4885RAB9A 1576/4885KDM4C 814/4885 |
| US-20230015242-A1 | TRIAZATRICYCLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | SSB, HLA-DRB1, PKD1 | NPC1 922/4885RAB9A 1576/4885KDM4C 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.